Advanced

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Kyle, R. A.; Durie, B. G. M.; Rajkumar, S. V.; Landgren, O.; Blade, J.; Merlini, G.; Kroeger, N.; Einsele, H.; Vesole, D. H. and Dimopoulos, M., et al. (2010) In Leukemia 24(6). p.1121-1127
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering... (More)
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010 (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
MGUS, International Myeloma Working Group, myeloma, monoclonal gammopathy of undetermined significance, smoldering multiple
in
Leukemia
volume
24
issue
6
pages
1121 - 1127
publisher
Nature Publishing Group
external identifiers
  • wos:000278575400003
  • scopus:77954610729
ISSN
1476-5551
DOI
10.1038/leu.2010.60
language
English
LU publication?
yes
id
72c6e179-5f02-4989-a57e-83864ed52b3c (old id 1630894)
date added to LUP
2010-07-22 16:19:29
date last changed
2018-07-08 03:45:21
@article{72c6e179-5f02-4989-a57e-83864ed52b3c,
  abstract     = {Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein &lt; 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010},
  author       = {Kyle, R. A. and Durie, B. G. M. and Rajkumar, S. V. and Landgren, O. and Blade, J. and Merlini, G. and Kroeger, N. and Einsele, H. and Vesole, D. H. and Dimopoulos, M. and San Miguel, J. and Avet-Loiseau, H. and Hajek, R. and Chen, W. M. and Anderson, K. C. and Ludwig, H. and Sonneveld, P. and Pavlovsky, S. and Palumbo, A. and Richardson, P. G. and Barlogie, B. and Greipp, P. and Vescio, R. and Turesson, Ingemar and Westin, J. and Boccadoro, M.},
  issn         = {1476-5551},
  keyword      = {MGUS,International Myeloma Working Group,myeloma,monoclonal gammopathy of undetermined significance,smoldering multiple},
  language     = {eng},
  number       = {6},
  pages        = {1121--1127},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management},
  url          = {http://dx.doi.org/10.1038/leu.2010.60},
  volume       = {24},
  year         = {2010},
}